Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system.
about
Useful Interplay Between Spontaneous ADR Reports and Electronic Healthcare Records in Signal DetectionLiver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting systemPaediatric pharmacovigilance: use of pharmacovigilance data mining algorithms for signal detection in a safety dataset of a paediatric clinical study conducted in seven African countriesAssociation Patterns in Open Data to Explore Ciprofloxacin Adverse EventsComputational approaches for pharmacovigilance signal detection: toward integrated and semantically-enriched frameworksGeneralized enrichment analysis improves the detection of adverse drug events from the biomedical literatureUsing aggregated, de-identified electronic health record data for multivariate pharmacosurveillance: a case study of azathioprine.Toward enhanced pharmacovigilance using patient-generated data on the internetAssessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS database.Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System.Publisher’s Note:Abstraction for data integration:Fusing mammalian molecular, cellular and phenotype big datasets for better knowledge extraction.A Method to Combine Signals from Spontaneous Reporting Systems and Observational Healthcare Data to Detect Adverse Drug Reactions.Prediction of black box warning by mining patterns of Convergent Focus Shift in clinical trial study populations using linked public dataData mining differential clinical outcomes associated with drug regimens using adverse event reporting data.Validation of New Signal Detection Methods for Web Query Log Data Compared to Signal Detection Algorithms Used With FAERS.Drug Safety Monitoring in Children: Performance of Signal Detection Algorithms and Impact of Age StratificationMedication-wide association studies.Improved statistical signal detection in pharmacovigilance by combining multiple strength-of-evidence aspects in vigiRank.Similarity-based modeling applied to signal detection in pharmacovigilance.Ongoing challenges in pharmacovigilance.Text mining for adverse drug events: the promise, challenges, and state of the art.Automatically Recognizing Medication and Adverse Event Information From Food and Drug Administration's Adverse Event Reporting System Narratives.A time-indexed reference standard of adverse drug reactions.3D pharmacophoric similarity improves multi adverse drug event identification in pharmacovigilance.Pharmacovigilance in oncology: evaluation of current practice and future perspectives.Exploring adverse drug events at the class level.Arrhythmia associated with buprenorphine and methadone reported to the Food and Drug AdministrationIntegrating Multiple Evidence Sources to Predict Adverse Drug Reactions Based on a Systems Pharmacology Model.Exposure of drugs for hypertension, diabetes, and autoimmune disease during pregnancy and perinatal outcomes: an investigation of the regulator in JapanDetection of drug-drug interactions through data mining studies using clinical sources, scientific literature and social media.Signal detection using change point analysis in postmarket surveillanceThe Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project.A method for systematic discovery of adverse drug events from clinical notesMining clinical text for signals of adverse drug-drug interactions.The Weber effect and the United States Food and Drug Administration's Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010.Discovering associations between adverse drug events using pattern structures and ontologies.Reverse translation of adverse event reports paves the way for de-risking preclinical off-targets.Using Multiple Pharmacovigilance Models Improves the Timeliness of Signal Detection in Simulated Prospective Surveillance.Adverse events associated with incretin-based drugs in Japanese spontaneous reports: a mixed effects logistic regression modelCan Disproportionality Analysis of Post-marketing Case Reports be Used for Comparison of Drug Safety Profiles?
P2860
Q27335410-840EAD4A-33A7-4B4C-8173-C12C4787278DQ28257188-D620643B-F899-4607-8028-F17B28C1D32AQ28538338-EE91340B-A340-4FA8-85E2-E961C31F1D8FQ28602965-6F6EE623-25D6-4E75-A74B-70F97544ABF2Q28651547-26969A4A-4F6D-4FF3-98FD-3481087FB7D2Q28829259-EC5742FB-8659-40AA-8179-240B5B5D678FQ30687155-EBFBB198-7E28-4BE7-B273-B08135E2DADCQ30796597-C606F8F4-C061-4473-A713-83C491B908CBQ30852962-7EF05212-7D99-494F-9EC3-033B3449F9F8Q30884142-D5561138-C5FF-436F-9A97-299CE67F116EQ30976077-FCD4C7C2-3AF9-4444-8AB0-246CEED6FCCAQ30979182-D56F3D22-4E9E-4034-9FF4-6A1C1F5B5729Q31043369-88F1F525-24A3-4E37-9E62-7F081E2B3E60Q31114073-9468CA03-83AD-414D-9BF3-AE017576FD26Q31159192-1A1BE3FC-60BC-4531-BA58-97C6275CCE11Q33432682-1FF1274E-2882-4BBF-B625-C67E9FF5DA57Q33633627-78FFBFDC-94D5-4798-8628-F58253529CA8Q34051874-DE457992-7293-4F06-A5DE-9AB942EF4051Q34413023-19761D10-DDE8-419A-9613-8F20B9C8170EQ34417013-FF18F975-FAC1-441B-A070-C706065D3A44Q34442663-736DB706-0620-4811-9B3D-0C44836E243BQ34881857-07C067E5-233F-4A1D-A375-0F79F72E3B67Q35012194-A2E0C1CC-94E6-44D6-8EA6-9433C9E177D6Q35153278-44A2843B-DD8F-4B0C-BFA6-9CC15A32E987Q35183601-A23DA4F4-1858-4D05-B1CA-8047A5981FBEQ35559500-52F6576C-27B9-4BFF-8139-F275986240DEQ35907781-29BB4352-1B14-4FE0-B203-2AD4E486D86FQ36118289-42D48023-B82D-4795-90E2-A4C757B4637FQ36152855-84D910AC-D4A9-4A21-992F-FFC5DA1C0693Q36320218-B09DAD7E-20CB-4B8A-BB3C-2C65ADB1B8BDQ36402604-6EBBD796-CB69-447B-A6C0-6F5BB6FAA11BQ36460550-57E682CA-0529-4A34-A987-EAD3C7338E3BQ37040215-B5E113C0-4A5E-4913-8023-4AFE7157FD3AQ37598930-01C08A34-C604-4388-9ABD-3B3BD860C49BQ37683523-EDEEB2D5-7C7A-436B-9106-88E2E1815CCBQ38371804-16515CB1-CFDE-4A08-B63C-C0786E63C830Q38635246-1F789CD1-A613-41DD-B773-6D9D83633FFDQ38701074-A3ACFBCF-1006-4F0F-91CF-8DF4AC6AC17DQ38893468-62FBD1A8-5AC6-4576-AC2E-694571E47C5EQ38948844-3026DDE0-F18E-4A2F-BC43-D66811EEE8D1
P2860
Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 February 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Performance of pharmacovigilan ...... dverse event reporting system.
@en
Performance of pharmacovigilan ...... dverse event reporting system.
@nl
type
label
Performance of pharmacovigilan ...... dverse event reporting system.
@en
Performance of pharmacovigilan ...... dverse event reporting system.
@nl
prefLabel
Performance of pharmacovigilan ...... dverse event reporting system.
@en
Performance of pharmacovigilan ...... dverse event reporting system.
@nl
P2093
P2860
P356
P1476
Performance of pharmacovigilan ...... dverse event reporting system.
@en
P2093
P2860
P304
P356
10.1038/CLPT.2013.24
P407
P577
2013-02-11T00:00:00Z